Fundz

Who to call at Werewolf Therapeutics, and when

Fundz watches for the moments Werewolf Therapeutics starts buying, and tells you who to reach.

  • An alert the day Werewolf Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Werewolf Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Werewolf Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Werewolf Therapeutics Announces Pipeline Update and Strategic Partnership Plans

Dec 18, 2025

Contract Type

partnership

WatertownBiotechnologyHealthcareHealth CareTherapeutics

Description

On December 18, 2025, Werewolf Therapeutics, Inc. released an update on its clinical pipeline and ongoing studies. The company highlighted its INDUKINE programs, particularly WTX-124 and WTX-330, and announced its intention to seek strategic partnerships for their further development. Recent data from trials demonstrated promising results in cancer treatments, suggesting potential for significant therapeutic advancements

Company Information

Company

Werewolf Therapeutics

Location

200 Talcott Ave, 2nd Floor

Watertown, Massachusetts, United States

About

Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINETM molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma.

Related People

Dan
Senior decision-maker at this company
••••••••@••••••••

See Dan's verified email →

Steven
Likely contact at this company
••••••••@••••••••

See Steven's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Werewolf Therapeutics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Werewolf Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.